FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an isolated antibody specifically binding an extracellular domain of the human and mouse inducible T-cell co-stimulator (ICOS), as well as to a composition containing it. A host cell in vitro for the expression of the above-mentioned antibody is also disclosed.
EFFECT: invention is effective for the stimulation of a T-cell immune response, as well as for the treatment of cancer.
26 cl, 45 dwg, 32 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
| ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS FOR USE THEREOF | 2016 |
|
RU2729379C1 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
